Scarica l'app Stockscreener
30.44
3.12%
-0.98
Dopo l'orario di chiusura:
30.44
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TVTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$31.42
Aprire:
$30.69
Volume 24 ore:
1.15M
Relative Volume:
0.61
Capitalizzazione di mercato:
$2.81B
Reddito:
$490.73M
Utile/perdita netta:
$-50.26M
Rapporto P/E:
-50.48
EPS:
-0.603
Flusso di cassa netto:
$-20.37M
1 W Prestazione:
+9.03%
1M Prestazione:
+3.08%
6M Prestazione:
+25.68%
1 anno Prestazione:
+69.68%
Intervallo 1D:
$30.22
$31.35
Intervallo di 1 settimana:
$27.14
$31.76
Portata 52W:
$12.91
$42.13
Travere Therapeutics Inc Stock (TVTX) Company Profile
Nome
Travere Therapeutics Inc
Settore
Industria
Telefono
888-969-7879
Indirizzo
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
30.44 | 2.81B | 490.73M | -50.26M | -20.37M | -0.603 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-31 | Reiterato | Citigroup | Buy |
| 2025-06-11 | Reiterato | Citigroup | Buy |
| 2025-06-11 | Ripresa | H.C. Wainwright | Buy |
| 2025-01-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-09 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-03-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-12-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-11-20 | Iniziato | Citigroup | Neutral |
| 2023-09-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Ripresa | Evercore ISI | Outperform |
| 2023-07-21 | Iniziato | JP Morgan | Overweight |
| 2023-06-07 | Ripresa | Piper Sandler | Neutral |
| 2023-05-22 | Iniziato | TD Cowen | Outperform |
| 2023-05-05 | Aggiornamento | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-21 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2022-12-14 | Iniziato | Stifel | Hold |
| 2022-12-05 | Iniziato | Wells Fargo | Overweight |
| 2022-09-21 | Iniziato | Bryan Garnier | Sell |
| 2022-07-14 | Ripresa | Canaccord Genuity | Buy |
| 2022-03-31 | Iniziato | Piper Sandler | Overweight |
| 2022-02-28 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-26 | Downgrade | Wedbush | Outperform → Neutral |
Mostra tutto
Travere Therapeutics Inc Borsa (TVTX) Ultime notizie
Buyback Watch: Is Travere Therapeutics Inc trading at a discount2026 Macro Moves & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Palisades Investment Partners LLC Invests $5.26 Million in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) CEO Eric Dube Sells 60,000 Shares - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Insider Sells $300,000.00 in Stock - MarketBeat
Travere therapeutics CEO Dube sells $1.8m in TVTX stock By Investing.com - Investing.com Canada
Travere therapeutics chief legal officer sells $300k in TVTX stock - Investing.com
Travere therapeutics chief legal officer sells $300k in TVTX stock By Investing.com - au.investing.com
Travere Therapeutics (TVTX) CEO sells 60K shares after option exercise - Stock Titan
Travere (NASDAQ: TVTX) CLO exercises options, pre-planned sale of 10K shares - Stock Titan
Travere Awaits FDA FILSPARI Ruling As Valuation Gap Draws Attention - finance.yahoo.com
(TVTX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
TVTX (NASDAQ: TVTX) files Form 144 for 60,000-share sale - Stock Titan
Elizabeth Reed registers sale of 10,000 TVTX shares (TVTX) via option exercise - Stock Titan
Hennion & Walsh Asset Management Inc. Increases Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
A Look At Travere Therapeutics (TVTX) Valuation After Recent Share Price Pullback - simplywall.st
Tudor Investment Corp Cuts Stake in Travere Therapeutics - National Today
Tudor Investment Corp ET AL Cuts Stake in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere, CSL gets standard EU approval for kidney disorder treatment - MSN
JPMorgan Chase Cuts Travere Therapeutics Price Target - National Today
Vanguard disaggregates holdings; reports 0 TVTX shares (Vanguard) - Stock Titan
Travere Therapeutics, Inc. $TVTX Shares Purchased by Assenagon Asset Management S.A. - MarketBeat
J.P. Morgan Gives a Buy Rating to Travere Therapeutics (TVTX) - The Globe and Mail
Aug Spikes: Should value investors consider Travere Therapeutics Inc2026 Price Swings & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Travere Therapeutics price target lowered to $41 from $44 at JPMorgan - TipRanks
Earnings Risk: Is Cayson Acquisition Corp Equity Right stock a falling knife or bargain buy2026 Volatility Report & High Accuracy Swing Trade Signals - baoquankhu1.vn
FOMO Trade: Is Snail Inc forming bullish engulfing patternsMarket Trend Review & Weekly Top Gainers Trade List - baoquankhu1.vn
JPMorgan Chase & Co. Has Lowered Expectations for Travere Therapeutics (NASDAQ:TVTX) Stock Price - MarketBeat
JP Morgan Lowers Price Target for TVTX to $41.00, Maintains Over - GuruFocus
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Travere Therapeutics (TVTX) Gains Attention with Potential FDA A - GuruFocus
Citi opens ‘upside 90-day catalyst watch’ on Travere Therapeutics - TipRanks
Citi Lifts Travere Therapeutics (TVTX) PT to $34 on Strong Q2 and Upcoming FDA Catalysts - MSN
A Look At Travere Therapeutics (TVTX) Valuation After Recent Share Price Volatility - simplywall.st
Travere Therapeutics (TVTX) reports 144% annual growth in Filspari sales for 2025 - MSN
Responsive Playbooks and the TVTX Inflection - Stock Traders Daily
Travere Therapeutics, Inc. (TVTX) positioned for long-term growth in rare disease market - MSN
Highs Report: Can Travere Therapeutics Inc be recession proofShare Buyback & Growth Focused Investment Plans - baoquankhu1.vn
Is Travere Therapeutics (TVTX) Pricing Signal An Opportunity After Recent Share Price Pullback? - simplywall.st
Travere Therapeutics Inc SEC Filings - Stock Titan
TVTX SEC FilingsTravere Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
TVTX Earnings History & Surprises | EPS & Revenue Results | TRAVERE THERAPEUTICS INC (NASDAQ:TVTX) - ChartMill
Travere Therapeutics (NASDAQ:TVTX) Insider Sells $280,900.00 in Stock - MarketBeat
Travere Therapeutics (TVTX) CLO exercises options and sells 10K shares - Stock Titan
HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs - MSN
Cinctive Capital Management LP Makes New $2.26 Million Investment in Travere Therapeutics, Inc. $TVTX - MarketBeat
Earnings Recap: Is Travere Therapeutics Inc stock heavily shorted2026 Technical Patterns & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
[144] Travere Therapeutics, Inc. SEC Filing - Stock Titan
166,000 Shares in Travere Therapeutics, Inc. $TVTX Purchased by Apis Capital Advisors LLC - MarketBeat
How Investors Are Reacting To Travere Therapeutics (TVTX) FILSPARI Momentum And Mirum Milestone Windfall - Sahm
Understanding the Setup: (TVTX) and Scalable Risk - Stock Traders Daily
Travere Therapeutics Inc Azioni (TVTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):